Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230036/S013

Esprit BTK Everolimus Eluting Resorbable Scaffold System

ABBOTT MEDICAL · Decision date Aug 8, 2025

FDA DECISIONP230036/S013

What did the FDA approve?

FDA records P230036/S013 as a supplement to PMA P230036, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Aug 8, 2025.

FDA approval order statement

approval of revisions to the Esprit BTK-PAS New Enrollment Study protocol (ABT-CIP-10519 Ver. C)
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Cardiovascular
Decision date
Aug 8, 2025
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P230036/S013
Regulatory pathway
PMA supplement
Product code
NXW
Decision code
APPR
Decision date
Aug 8, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Scaffold, infrapopliteal, absorbable.

Product code
NXW
FDA device class
3

For the original device and its historical approval scope, see PMA P230036. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230036 · Original PMA

    Esprit BTK Everolimus Eluting Resorbable Scaffold System

  2. P230036/S013 received

    Application receipt date recorded by FDA.

  3. P230036/S012 · Related supplement

    Esprit BTK Everolimus Eluting Resorbable Scaffold System

  4. P230036/S013 · FDA decision

    Normal 180 Day Track No User Fee

  5. P230036/S014 · Related supplement

    Esprit BTK Everolimus Eluting Resorbable Scaffold System

  6. P230036/S015 · Related supplement

    Esprit BTK Everolimus Eluting Resorbable Scaffold System

  7. P230036/S016 · Related supplement

    Esprit BTK RX System; Esprit BTK OTW System

  8. P230036/S018 · Related supplement

    Esprit BTK Everolimus Eluting Resorbable Scaffold System

  9. P230036/S017 · Related supplement

    Esprit BTK Everolimus Eluting Resorbable Scaffold System

  10. P230036/S020 · Related supplement

    Esprit BTK Everolimus Eluting Resorbable Scaffold System

Timeline entries are records held by MedtechLedger for P230036. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230036

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Medical

Headquarters
Not reported
Brand website
abbott.com
FDA applicant address
3200 Lakeside Dr., Santa Clara, CA, 95054

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records